Technical Analysis for UTHR - United Therapeutics Corporation

Grade Last Price % Change Price Change
C 233.97 -0.77% -1.81
UTHR closed down 0.77 percent on Monday, March 18, 2024, on 1.14 times normal volume.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
20 DMA Support Bullish 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Down 3 Days in a Row Weakness -0.77%
Down 4 Days in a Row Weakness -0.77%
Overbought Stochastic Strength -1.74%
Down 3 Days in a Row Weakness -1.74%
Slingshot Bullish Bullish Swing Setup -3.03%

   Recent Intraday Alerts

Alert Time
20 DMA Support about 19 hours ago
Down 2 % about 20 hours ago
Fell Below 20 DMA about 20 hours ago
Down 1% about 21 hours ago
Fell Below Previous Day's Low about 21 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

United Therapeutics Corporation Description

United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product is Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops oral treprostinil, an orally delivered prostacyclin analog for treatment of pulmonary hypertension; Ch14.18 MAb, an antibody in Phase III clinical trials for the treatment of neuroblastoma; Beraprost 314d, which is entering Phase III clinical trails for the treatment of PAH; PLacental eXpanded cells, which are entering a Phase I trial for the treatment of PAH; and 8H9 MAb, an antibody that is under Phase I clinical trial for the treatment of metastatic brain cancer. Further, the company is involved in the pre-clinical stage of developing TransCon Treprostinil, TransCon Beraprost, and glycobiological antiviral agents for the treatment of infectious diseases, such as Hepatitis C; and engineered lungs and lung tissue, which can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Infectious Diseases Alcohol Organic Compounds Chemical Compounds Hypertension Blastoma Pulmonary Arterial Hypertension Hepatitis C Pulmonary Hypertension Neuroblastoma Brain Cancer Lung Diseases Treprostinil Chronic And Life Threatening Conditions Oral Therapy Treatment Of Infectious Diseases

Is UTHR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 261.48
52 Week Low 204.44
Average Volume 391,420
200-Day Moving Average 227.77
50-Day Moving Average 223.27
20-Day Moving Average 231.86
10-Day Moving Average 239.53
Average True Range 6.28
RSI (14) 53.92
ADX 43.72
+DI 26.65
-DI 20.04
Chandelier Exit (Long, 3 ATRs) 231.52
Chandelier Exit (Short, 3 ATRs) 230.45
Upper Bollinger Bands 250.67
Lower Bollinger Band 213.04
Percent B (%b) 0.56
BandWidth 16.23
MACD Line 5.21
MACD Signal Line 5.23
MACD Histogram -0.0159
Fundamentals Value
Market Cap 11 Billion
Num Shares 47 Million
EPS 18.13
Price-to-Earnings (P/E) Ratio 12.91
Price-to-Sales 4.53
Price-to-Book 1.75
PEG Ratio 1.30
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 245.15
Resistance 3 (R3) 244.92 240.96 243.29
Resistance 2 (R2) 240.96 238.11 241.08 242.67
Resistance 1 (R1) 237.47 236.35 235.49 237.70 242.05
Pivot Point 233.51 233.51 232.52 233.62 233.51
Support 1 (S1) 230.01 230.66 228.03 230.24 225.89
Support 2 (S2) 226.05 228.90 226.17 225.27
Support 3 (S3) 222.56 226.05 224.65
Support 4 (S4) 222.79